Navigation Links
Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
Date:11/11/2009

icularly those anticipating future clinical and business prospects for KRX-0401 (perifosine), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete clinical trials for KRX-0401; our ability to meet anticipated development timelines for KRX-0401 due to recruitment, clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website and in the American Society of Hematology's website is not incorporated by reference into this press release and is included as an inactive textual reference only.

    KERYX CONTACT:
        Lauren Fischer
        Director - Investor Relations
        Keryx Biopharmaceuticals, Inc.
        Tel: 212.531.5965
        E-mail: lfischer@keryx.com

SOURCE Keryx Biopharmaceuticals, Inc.


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
4. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
5. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
6. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
7. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH) today ... 2014.  The Company reported second quarter net sales of ... constant currency over the second quarter of 2013.  Diluted ... and $1.49 adjusted, an increase of 4.2% adjusted over ... quarter was marked by solid sales growth in a ...
(Date:7/24/2014)... 24, 2014 Cognizant ... that it has been selected by ... with membership representation from 19 major pharmaceutical ... that will transform the way clinical sites ... TransCelerate BioPharma Inc. is dedicated to making ...
(Date:7/23/2014)... ALTO, Calif., July 23, 2014  Varian Medical Systems ... earnings of $1.02 per diluted share in the third ... impacted by about $0.06 per diluted share due to ... portion of Varian,s existing equity investment in Augmenix, a ... company-wide revenues totaled $748 million for the third quarter ...
Breaking Medicine Technology:Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 2Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 3Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 4Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 5Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 6Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 7Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 8Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 9Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 10Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 11Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 12Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 13Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 14Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 15Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 16Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 17Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 18Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 19Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 20Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 21Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 22Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 23Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 24TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 2TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 3TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 4TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 3Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 4Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 6Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 7Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 8Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 9
... LOUIS, Oct. 30 Stereotaxis received notice that the ... for distribution in the European market. The product ... on-going co-development agreement between Stereotaxis and Biosense Webster to ... the Niobe Magnetic Navigation System (MNS). , A ...
... COLUMBUS, Ohio, Oct. 29 Mettler-Toledo International Inc. (NYSE: MTD ) ... the highlights: , Sales in local currency declined by ... a 2% negative currency impact. , Net earnings ... in the third quarter of 2008. Adjusted EPS was $1.36, ...
Cached Medicine Technology:Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter 2Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 2Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 3Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 4Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 5Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 6Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 7Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 8Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 9Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 10Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 11Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 12Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 13
(Date:7/24/2014)... (PRWEB) July 24, 2014 The North American ... $1.6 billion in 2014, and is expected to register a ... U.S. has been the biggest market for the air and ... the U.S. market has witnessed budget cuts as well. , ... missile defense radar market report, to get an idea of ...
(Date:7/24/2014)... 23, 2014 (HealthDay News) -- Even though its use is ... as Tylenol -- does not help treat lower back pain, ... found the drug was no more effective than a dummy ... back pain. Besides showing no effect in easing discomfort, ... improving sleep woes tied to back pain, nor did it ...
(Date:7/24/2014)... at emergency departments can be reduced by enabling patients ... their doctor,s surgery. This is just one of several ... researchers at the University of Bristol. , Called ,Primary ... systematic reviews, the report has been compiled by researchers ... looked at evidence from studies around the world. They ...
(Date:7/24/2014)... and Rhode Island have identified two previously ... of laparoscopically adjustable gastric bands. Adding widespread ... the superolateral band margin by more than ... presence of an air-fluid,level above the band ... will aid them in diagnosing affected bariatric ...
(Date:7/24/2014)... were found commonly in streams throughout the Midwest, ... the first broad-scale investigation of neonicotinoid insecticides in ... first conducted within the United States. , Effective ... use of neonicotinoid insecticides has dramatically increased over ... in the Midwest. The use of clothianidin, ...
Breaking Medicine News(10 mins):Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 2Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 3Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 4Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 2Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 3Health News:Seeing the same GP at every visit will reduce emergency department attendance 2Health News:Corn & soy insecticides similar to nicotine found widespread in Midwest rivers -- USGS news 2
... to Create Sustainable Breast Cancer Programs in ... Countries with Highest Potential, Greatest Need, BUDAPEST, Hungary, ... receiving a breast cancer diagnosis each year, it has ... about this,life-threatening disease. Building on the U.S.-Middle East Partnership ...
... experts say , , FRIDAY, Sept. 28 (HealthDay News) -- ... autoimmune disease lupus is building up steam, a group ... researchers from across the United States spoke at a ... of the improving outlook for patients with systemic lupus ...
... According to the American Society of,Plastic ... Latinos received,physician-administered aesthetic procedures like BOTOX(R) Cosmetic ... board certified,dermatologist in Miami, says that given ... that women make informed decisions when,considering these ...
... TJ Enterprises, LLC,announced that its product, ... the treatment of baby digestive discomfort including ... the U.S. Food and Drug,Administration (FDA) confirmed ... a non-homeopathic gripe water, Apple Flavored Baby,s,Bliss, ...
... WAYNE, Pa., Sept. 28 Escalon Medical Corp.,(Nasdaq: ... quarter and,twelve months ended June 30, 2007. For ... increased,to $38,837,780 compared with $29,790,698 in fiscal 2006. This ... million lump sum settlement payment,from IntraLase Corp. to the ...
... NEW ORLEANS, Sept. 28 Sanarus Medical today ... select centers across,the country. These Centers, including breast ... partnership with Sanarus to,increase the awareness and availability ... benign breast tumors, known as,fibroadenomas. Sanarus will host ...
Cached Medicine News:Health News:Susan G. Komen for the Cure Launches Unprecedented Global Expansion Program in 10 Countries 2Health News:Susan G. Komen for the Cure Launches Unprecedented Global Expansion Program in 10 Countries 3Health News:Better Lupus Treatments on the Horizon 2Health News:Better Lupus Treatments on the Horizon 3Health News:Better Lupus Treatments on the Horizon 4Health News:After Infant Gripe Water Recall Scare, Homeopathic Medicine Offers Safe Alternative 2Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 2Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 3Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 4Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 5Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 6Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 7Health News:Sanarus Announces Partnership With Leading US Breast Care Physicians for the Next Generation Visica 2(TM) Treatment System for Fibroadenomas 2
... three styles. Each style has multiple sizes. ... popular style. Pectoral Implants are available non-sterile ... individually, not in pairs. Both styles are ... for a specific side and are directional. ...
... The IQmarkTM Diagnostic Workstation Software ... Software System that digitally stores many ... Designed with Microsofts open-architecture products in ... as EMR integration (using ActiveX controls), ...
... Digital ECG is a highly advanced and refined ... personal computer. Everything you need to get up ... and operating costs of the IQmark Digital ECG ... ECG machines (even including the cost of the ...
... Trichloroacetic acid (TCA) peels are often ... substantial discomfort. PCA Professional™ TCA peels are ... solutions are blends formulated with many ingredients ... plumping phytohormones and kojic and azelaic acids ...
Medicine Products: